Latest News
-
New Product Launch – Ceradan® Advanced Emollient Wash, a unique 2-in-1 antiseptic emollient wash
13 Feb 2023
Hyphens Pharma expands the Ceradan® Advanced range with a new product, Ceradan® Advanced Emollient Wash! It is a unique 2-in-1 antiseptic emollient wash scientifically formulated for eczema-prone skin.Formulated with carefully selected gentle antiseptic, Octenidine, it protects against bacteria that canHyphens Pharma expands the Ceradan® Advanced range with a new product, Ceradan® Advanced Emollient Wash! It is a unique 2-in-1 antiseptic emollient wash scientifically formulated for eczema-prone skin.
Formulated with carefully selected gentle antiseptic, Octenidine, it protects against bacteria that can aggravate eczema. Enriched with 3:1:1 ceramide-dominant ratio of essential skin lipids in a pH-balanced system, it moisturises and strengthens the skin’s protective barrier while it cleanses effectively.
Clinically tested hypoallergenic. Suitable as a gentle moisturising face and body wash for all ages.
-
Hyphens Pharma’s Meradan® cream launches in Indonesia
05 Dec 2022
Meradan® is a steroid cream containing 0.1% mometasone furoate and physiological lipids including ceramide found in Ceradan® cream. This formula is developed with skin barrier repair properties in mind. This is important because steroid creams are known to cause skinMeradan® is a steroid cream containing 0.1% mometasone furoate and physiological lipids including ceramide found in Ceradan® cream. This formula is developed with skin barrier repair properties in mind. This is important because steroid creams are known to cause skin thinning. Therefore, Meradan® confers an advantage over typical steroid creams that were formulated without skin barrier repair properties.
Meradan® is available only through prescription by doctors including dermatologists and paediatricians. It is approved for use in skin diseases that cause inflammation and itch, such as conditions like eczema, psoriasis, and skin rash.
Read our media release here for more details.
-
Hyphens Pharma’s TDF® Blu Voile sunscreen scientifically proven to protect skin against blue light at cellular level
15 Sep 2022
We are pleased to announce results of a clinical study on “The protective effect of a novel sunscreen against blue light”, published recently in the International Journal of Cosmetic Science, shows that TDF® Blu Voile Sunscreen provides 82% protection atWe are pleased to announce results of a clinical study on “The protective effect of a novel sunscreen against blue light”, published recently in the International Journal of Cosmetic Science, shows that TDF® Blu Voile Sunscreen provides 82% protection at the cellular level against the harmful effects of blue light irradiation.
TDF® Blu Voile Sunscreen also offers thorough and complete protection against UV-A/UV-B and blue light, versus conventional broad-spectrum sunscreens.
Read our media release here for more details.
-
Hyphens Pharma received patents in the US, Singapore and Malaysia for Ceradan® Advanced, in addition to UK
23 Feb 2022
The US, Singapore and Malaysia are the latest countries to grant patent approvals for the skin pH buffering technology used in Ceradan® Advanced. These patent approvals reaffirm the scientific value that underlies Ceradan® Advanced as the next-generation emollient therapy forThe US, Singapore and Malaysia are the latest countries to grant patent approvals for the skin pH buffering technology used in Ceradan® Advanced. These patent approvals reaffirm the scientific value that underlies Ceradan® Advanced as the next-generation emollient therapy for eczema-prone skin conditions. To date, there are four patent approvals, with 10 patents pending approval in countries/regions such as Vietnam, China, and Europe.
Learn more about the world’s first and most advanced emollient therapy:
-
Hyphens Pharma inked exclusive licensing deal of Ustekinumab biosimilar
14 Dec 2021
We are pleased to announce that we have signed an exclusive license and supply agreement with Favorex Pte Ltd, a subsidiary of DKSH, to commercialise Ustekinumab biosimilar produced by Alvotech, in Singapore, Malaysia and the Philippines. Alvotech is a multinationalWe are pleased to announce that we have signed an exclusive license and supply agreement with Favorex Pte Ltd, a subsidiary of DKSH, to commercialise Ustekinumab biosimilar produced by Alvotech, in Singapore, Malaysia and the Philippines. Alvotech is a multinational biopharmaceutical company that focuses on the development and manufacturing of high quality biosimilars for global markets.
The proposed Ustekinumab biosimilar, which is undergoing clinical studies, is a human monoclonal antibody that targets interleukin-12 (“IL-12”) and interleukin-23 (“IL-23”) for the treatment of immune mediated disorders like plaque psoriasis, psoriatic arthritis, and Crohn’s disease.
Read our media release here (PDF) for more details.
-
New Product Launch – Ceramoz® Mosquito Repellent Patch, a 100% natural patch that protects up to 12 hours
23 Sep 2021
Ceramoz mosquito repellent patch is created with 100% natural botanical ingredient – oil of lemon eucalyptus – for use in mosquito repellent, approved by US EPA, and has been proven to be effective in repelling mosquitoes, ticks and biting insectsCeramoz mosquito repellent patch is created with 100% natural botanical ingredient – oil of lemon eucalyptus – for use in mosquito repellent, approved by US EPA, and has been proven to be effective in repelling mosquitoes, ticks and biting insects for up to 12 hours in both outdoors and indoors environments.
-
New Product Launch – TDF Blu Voile, an advanced and complete sun protection
16 Apr 2021
Blu Voile is the only true complete sun protection that was formulated to shield from 90% blue light on top of UVA and UVB protection, preventing hyper pigmentation, melasma, and brown spots, more effectively than conventional sunscreens.Learn more about thisBlu Voile is the only true complete sun protection that was formulated to shield from 90% blue light on top of UVA and UVB protection, preventing hyper pigmentation, melasma, and brown spots, more effectively than conventional sunscreens.
Learn more about this advanced blue light shield and SPF50 sunscreen, PA+++:
https://www.tdf-derma.com/products/blu-voile-sunscreen-spf50-pa/ -
How A*STAR (Agency for Science, Technology and Research) played an important role in Hyphens Pharma’s transformation journey
18 Mar 2021
We have worked with the Skin Research Institute of Singapore (SRIS) and A*STAR’s Institute of Chemical and Engineering Sciences (ICES) on various R&D activities since 2014, targeting skin health issues such as atopic dermatitis and acne.In this video, discover howWe have worked with the Skin Research Institute of Singapore (SRIS) and A*STAR’s Institute of Chemical and Engineering Sciences (ICES) on various R&D activities since 2014, targeting skin health issues such as atopic dermatitis and acne.
In this video, discover how our research collaboration enabled Hyphens to bring Ceradan® Advanced to fruition and help people suffering from eczema.
A*STAR continues to be an important innovation partner for us, as we innovate and develop innovative products to improve the lives of people living with skin disorders.
Watch the video here.
-
Hyphens Pharma appoints exclusive distributor in South Korea for TDF® Fairence® T-Complex
18 Jan 2021
We have appointed JSPharma as an exclusive distributor of TDF® Fairence® T-Complex in South Korea. JSPharma’s key customers include medical clinics, hospitals, and burn centres covering medical specialists such as dermatologists, plastic surgeons and aesthetic doctors. It currently represents severalWe have appointed JSPharma as an exclusive distributor of TDF® Fairence® T-Complex in South Korea. JSPharma’s key customers include medical clinics, hospitals, and burn centres covering medical specialists such as dermatologists, plastic surgeons and aesthetic doctors. It currently represents several international brands from Europe and the United States.
Fairence® is a scientifically designed pigment lightening cream enhanced by Xcelarev®, a patented delivery system incorporating three key ingredients, namely Tranexamic acid, Niacinamide and Lactobionic acid, to tackle pigmentation issues such a melasma.
Read our media release here (PDF) for more details.
-
Hyphens Pharma broadens Ceradan® brand’s outreach to Mainland China
12 Nov 2020
We are delighted to welcome Shanghai Good Luck International Trading Co. Ltd. as an exclusive distributor of Ceradan®. Shanghai Good Luck has the integrated marketing capability and knowledge to sell and market professional products in the medical channel in allWe are delighted to welcome Shanghai Good Luck International Trading Co. Ltd. as an exclusive distributor of Ceradan®. Shanghai Good Luck has the integrated marketing capability and knowledge to sell and market professional products in the medical channel in all the major economic regions in Mainland China.
Under this partnership, they will be granted exclusive rights to distribute Ceradan® products, such as Ceradan® Skin Barrier Repair Cream, with the exception of Ceradan® Advanced.
Read our media release here (PDF) for more details.
-
Hyphens Pharma expands dermatology portfolio with hair growth products
03 Aug 2020
Hyphens Pharma has procured all rights, titles and interests in the trademarks of CG 210® and CG4S from Legacy Healthcare (Switzerland) SA for Singapore and Malaysia. The CG 210® product series such as the CG 210® Women lotion, CG 210®Hyphens Pharma has procured all rights, titles and interests in the trademarks of CG 210® and CG4S from Legacy Healthcare (Switzerland) SA for Singapore and Malaysia. The CG 210® product series such as the CG 210® Women lotion, CG 210® Men lotion, CG 210® Forte Lotion and the CG4S Shampoo, will be sold, marketed and distributed in these two countries. CG 210® stems from 10 years of hair science research.
CG 210® is a patented topical botanical hair growth-promoting agent based on Allium cepa (onion), Citrus medica limonum (lemon), Theobroma cacao (cocoa) and Paullinia cupana(guarana) that works via unique mechanisms of action. Its safety and efficacy have been demonstrated in more than 10 clinical studies involving close to 800 subjects with several publications. To date, over 2 million units have been sold worldwide.
-
New Product Launches! Ceradan® Gentle Cleanser and Ceradan® Hand Lotion Sanitiser
15 Jul 2020
Hyphens Pharma expands the Ceradan® range with two new products.Ceradan® Gentle Cleanser is a gentle, soap-free, face and body cleanser that not only hydrates and soothes, but also rebuilds the skin barrier as it cleans. It is hypoallergenic, free fromHyphens Pharma expands the Ceradan® range with two new products.
Ceradan® Gentle Cleanser is a gentle, soap-free, face and body cleanser that not only hydrates and soothes, but also rebuilds the skin barrier as it cleans. It is hypoallergenic, free from sodium lauryl sulphate/sodium laureth sulfate (SLS/SLES), paraben, colourants, and fragrances.
Ceradan® Hand Lotion Sanitiser is a high-performance hand lotion sanitiser that protects hands against harmful germs and moisturises with ceramide-dominant essential skin lipids to maintain a healthy skin protective barrier. Formulated with a pH of 5.5, it is hypoallergenic and free from colourants and fragrances.
Both the Ceradan® Gentle Cleanser and Ceradan® Hand Lotion Sanitiser are suitable for all skin types, including eczema-prone, dry and sensitive skin, and are currently available in retail pharmacies such as Guardian and Watsons.
To learn more about the new products, please visit your Ceradan website:
https://www.ceradan.com/
-
Hyphens Pharma receives UK patent for Ceradan® Advanced
15 Jul 2020
Ceradan® Advanced, a scientifically formulated emollient therapy for eczema-prone skin, has been granted patent in the United Kingdom (UK) and is pending approval in 13 countries/region such as Singapore, Malaysia, Vietnam, China, Europe, USA, etc.Ceradan® Advanced sustainably lowers the skinCeradan® Advanced, a scientifically formulated emollient therapy for eczema-prone skin, has been granted patent in the United Kingdom (UK) and is pending approval in 13 countries/region such as Singapore, Malaysia, Vietnam, China, Europe, USA, etc.
Ceradan® Advanced sustainably lowers the skin pH for up to 12 hours to induce skin lipids production and suppresses skin cell breakdown. This helps to accelerate optimal skin barrier repair and restoration.
To learn more about Ceradan® Advanced, please visit:
https://www.ceradan.com/advanced
-
Hyphens Pharma inked MoU with A*STAR’s A*ccelerate for R&D collaboration on dermatological products for skin disorders
21 Mar 2019
The latest MoU will build on prior partnership and further enhance the relationship between both organisations in research and development activities for dermatologicals and cosmeceuticals targeting eczema, acne and pigmentary disorders.Our collaboration with A*STAR through the MoU with A*ccelerate isThe latest MoU will build on prior partnership and further enhance the relationship between both organisations in research and development activities for dermatologicals and cosmeceuticals targeting eczema, acne and pigmentary disorders.
Our collaboration with A*STAR through the MoU with A*ccelerate is a reflection of our commitment to grow through innovation.
Read our media release here (PDF) for more details.
-
Launch of TDF Fairence® T-Complex
07 Jan 2019
TDF expanded its Hyperpigmentation range with an innovative pigmentation cream, Fairence® T-Complex which helps target dark spots and pigmented skin. It is scientifically designed with the Xcelarev® Technology which is a patented delivery system. Incorporated with 3 key ingredients, TranexamicTDF expanded its Hyperpigmentation range with an innovative pigmentation cream, Fairence® T-Complex which helps target dark spots and pigmented skin. It is scientifically designed with the Xcelarev® Technology which is a patented delivery system. Incorporated with 3 key ingredients, Tranexamic acid, Niacinamide and Lactobionic acid, the Xcelarev® Technology enhances skin lightening effect. Fairence® is also clinically tested hypoallergenic and is well tolerated.
-
Advancement in Atopic Dermatitis Symposium (AADS) – Bangkok, Thailand
24 Mar 2018
This year the theme of our biennial symposium was “Breakthroughs and Advances in Skin Health Science”. The event brought together over a hundred doctors and key opinion leaders from Indonesia, Malaysia, Myanmar, Philippines, Singapore and Vietnam. The full-day program was indeed thought-provoking, touching on the latest understanding and development in the atopic dermatitis and acne spheres.This year the theme of our biennial symposium was “Breakthroughs and Advances in Skin Health Science”. The event brought together over a hundred doctors and key opinion leaders from Indonesia, Malaysia, Myanmar, Philippines, Singapore and Vietnam. The full-day program was indeed thought-provoking, touching on the latest understanding and development in the atopic dermatitis and acne spheres.
-
Voted The Best Ceramide Moisturiser for Eczema-prone Skin
04 Jan 2018
We could not be more excited to announce that Ceradan Cream has been recently voted the best ceramide moisturiser for eczema-prone skin by Singapore’s Child magazine. To read more about the write up, please view the link below: http://singaporeschild.com.sg/sc-babies-kids-awards-2018-best-ceramide-moisturiser-for-eczema-prone-skin/We could not be more excited to announce that Ceradan Cream has been recently voted the best ceramide moisturiser for eczema-prone skin by Singapore’s Child magazine. To read more about the write up, please view the link below: http://singaporeschild.com.sg/sc-babies-kids-awards-2018-best-ceramide-moisturiser-for-eczema-prone-skin/ -
TDF Facelift Launch
02 Oct 2017
Formerly known as Therapeutic Dermatologic Formula, the brand has been given a fresh look! It is now officially TDF Derma Formula®. The clinically-premium look will further strengthen the medical positioning of the trusted brand by prescribers in the region. Please view the short video about TDF facelift below.Formerly known as Therapeutic Dermatologic Formula, the brand has been given a fresh look! It is now officially TDF Derma Formula®. The clinically-premium look will further strengthen the medical positioning of the trusted brand by prescribers in the region.
Please view the short video about TDF facelift below.
-
Launch of Ceradan® Soothing Gel
11 Sep 2017
Ceradan Soothing Gel is a specially formulated gel to provide optimal relief to itchy skin without unbearable smell and stinging sensation. Generally-speaking, itch is the most bothersome symptom for children with eczema-prone skin. Hence, breaking the itch-scratch cycle is essential as that would minimize scratching reducing further damage to the skin.Ceradan Soothing Gel is a specially formulated gel to provide optimal relief to itchy skin without unbearable smell and stinging sensation. Generally-speaking, itch is the most bothersome symptom for children with eczema-prone skin. Hence, breaking the itch-scratch cycle is essential as that would minimize scratching reducing further damage to the skin.
It contains menthol and polidocanol, both of which are proven to be effective in reducing itch. Ceradan Soothing Gel is recommended for 3 years and above.
-
Hyphens Pharma Tapped on A*STAR Technology to Drive Innovation in the Field of Dermatology
18 Nov 2016
Hyphens Pharma and Agency for Science, Technology and Research (A*STAR) inked a memorandum of understanding (MoU) on becoming strategic dialogue partners to explore collaboration in market-relevant projects in dermatology research and skin disorders.Hyphens Pharma is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES). The license was resulted from a Research Collaboration Agreement (RCA) with A*STAR in earlier years.
By leveraging on A*STAR’s research and development capabilities, we envisioned this will enable us to develop innovative and differentiated dermatological products to address unmet market needs. Dermatology is a key therapeutic focus field for Hyphens and we are encouraged to have A*STAR as our strategic dialogue partner.
-
Launch of Ceramoz®
01 Sep 2016
Ceramoz® Mosquito Repellent Cream is the latest addition to the Ceradan® range. It is specially formulated for people with sensitive skin to help protect them from mosquito bites and at the same time moisturise their skin. Ceramoz® is a hypoallergenic repellent cream that contains 10% DEET and enriched with ceramide which is an essential lipid in the skin barrier to provide moisturising effect. It is suitable for use in babies from 2 months onwards.
Ceramoz® Mosquito Repellent Cream is the latest addition to the Ceradan® range. It is specially formulated for people with sensitive skin to help protect them from mosquito bites and at the same time moisturise their skin. Ceramoz® is a hypoallergenic repellent cream that contains 10% DEET and enriched with ceramide which is an essential lipid in the skin barrier to provide moisturising effect. It is suitable for use in babies from 2 months onwards.
Ceramoz® has been tested according to WHO Guidelines and is approved by the Singapore National Environment Agency.
-
22nd Regional Conference of Dermatology (RCD), 21 – 24 April 2016 – Raffles City Convention Centre, Singapore
25 Apr 2016
Hyphens took centre stage as the sole Diamond Supporter of this event, which drew more than 1,000 delegates from around the region.We successfully achieved full house for two of our supported symposiums delivered by key speakers from Germany and Singapore.Hyphens took centre stage as the sole Diamond Supporter of this event, which drew more than 1,000 delegates from around the region.
We successfully achieved full house for two of our supported symposiums delivered by key speakers from Germany and Singapore. The first symposium was on the advancement in atopic dermatitis and COPES, featuring our study in collaboration with KK Women’s and Children’s Hospital and National Skin Centre (Ceradan®).
We also officially launched the iControl Eczema App, developed in conjunction with KK Women’s and Children’s Hospital and Nanyang Polytechnic.
-
2nd Advancement in Atopic Dermatitis Symposium (AADS), 10 May 2014 – Conrad Bali Resort & Spa, Indonesia
11 May 2014
Themed “Integrating Science with Experience for AD Management”, the symposium organised by Hyphens Pharma, aimed to provide new insights on management of difficult-to-treat atopic dermatitis (AD), patient education and the use of Ceradan® in the very young. We welcomed back ourThemed “Integrating Science with Experience for AD Management”, the symposium organised by Hyphens Pharma, aimed to provide new insights on management of difficult-to-treat atopic dermatitis (AD), patient education and the use of Ceradan® in the very young.
We welcomed back our keynote speaker, Prof Mike Cork, who delivered a concise lecture about his management of difficult AD and many delegates took away practical tips that were relevant and useful for their practices. Meanwhile, hospital department heads, Dr Mark Koh and Dr Hidajati, touched on patient education and case reports of Ceradan®.